Journal article

Recommendations for the use of pegylated interferon-alpha in the treatment of classical myeloproliferative neoplasms

Cecily J Forsyth, Wai-Hoong Chan, Andrew P Grigg, Nathalie C Cook, Steven W Lane, Kate L Burbury, Andrew C Perkins, David M Ross

INTERNAL MEDICINE JOURNAL | WILEY | Published : 2019

Abstract

The classical myeloproliferative neoplasms (MPN) are uncommon clonal haemopoietic malignancies characterised by excessive production of mature blood cells. Clinically, they are associated with thrombosis, haemorrhage, varying degrees of constitutional disturbance and a risk of progression to myelofibrosis or acute myeloid leukaemia. Many of the disease manifestations may be ameliorated by treatment with interferon-α (IFN), but its use in Australian MPN patients has been limited due to the inconvenience of frequent injections and side-effects. The pegylated form of IFN is a long-acting preparation, which is better tolerated, and its Pharmaceutical Benefits Scheme listing is likely to lead to ..

View full abstract